Form 4: Lexeo Therapeutics CEO Sells Shares to Cover Tax Obligations

Lexeo Therapeutics CEO Richard Nolan Townsend sold 4,326 shares of common stock on February 19, 2025, to cover tax obligations related to the release of restricted stock units.

Summary

• On February 19, 2025, Richard Nolan Townsend, the CEO of Lexeo Therapeutics, sold 4,326 shares of common stock.
• The sale was executed at a price of $4.413 per share.
• This transaction was to cover tax obligations arising from the release of restricted stock units (RSUs).
• Following the transaction, Townsend directly owns 220,119 shares, which includes 136,562 RSUs.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (sale of shares to cover tax obligations). It doesn't convey any particularly positive or negative sentiment about the company's prospects.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among executives of publicly traded companies. This is a routine transaction and doesn't necessarily indicate a change in the executive's confidence in the company.

Stakeholder Impact

• The sale of shares by the CEO could have a minor, temporary impact on the stock price.

Key Dates

Keywords

LXEO, Lexeo Therapeutics, Richard Nolan Townsend, CEO, Form 4, Share Sale, Restricted Stock Units, Tax Obligations, Beneficial Ownership